Evaluation of the Hereditary Component of Localized Prostate Cancer
Courtney Schroeder
Primary Investigator
Brief description of study
Detailed description of study
- Participants will complete a blood draw for genetic testing.
- Collection of blood samples from healthy, non-pregnant adults who weigh at least 110 pounds (49.9 kg). Amount drawn will not exceed 550 ml in an 8 week period and collection will not occur more frequently than 2 times per week.
- Collection of blood samples from adults and children, with consideration to the age, weight, and health of the subjects, along with the collection procedure, the amount of blood to be collected and the frequency of collection. Amount drawn will not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection will not occur more frequently than 2 times per week.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prostate cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Male
Inclusion criteria
a) African American males with a diagnosis of localized prostate cancer
b) Men 50 years or younger with a diagnosis of localized prostate cancer
c) Clinically significant prostate cancer (Gleason score of ≥7) and a first degree relative (father, brother, or son) with a diagnosis of prostate cancer
d) Clinically significant prostate cancer (Gleason score of ≥7) and a family history of;
1. First degree relative with breast cancer diagnosed younger than age 50
2. First or second degree relative with ovarian cancer, pancreatic cancer or metastatic prostate cancer
3. Ashkenazi Jewish ancestry
e) High-risk non-metastatic disease classified by the High Risk D’Amico criteria as PSA >20, Gleason score of ≥8 or stage T2c-3a
q23235
Exclusion criteria
a) are unable to offer informed consent
b) have been diagnosed with metastatic prostate cancer
c) have been diagnosed with another type of cancer previously, excluding skin cancer
